DUL:ETR
Alnylam Pharmaceuticals, Inc.
209,40 €
arrow_upward
+0,67%(+1,40) 1D
20. okt., 17.35.44 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for DUL...
Ã…bn
208,40 €
Høj
209,40 €
Lav
208,40 €
Markedsværdi
30,87Â mia.
Gns. vol.
37,00
Volumen
0,00
Højeste i 52 uger
417,40 €
Laveste i 52 uger
177,10 €
Antal ansatte
2Â t
Ã…bn
208,40 €
Høj
209,40 €
Lav
208,40 €
Markedsværdi
30,87Â mia.
Gns. vol.
37,00
Volumen
0,00
Højeste i 52 uger
417,40 €
Laveste i 52 uger
177,10 €
Antal ansatte
2Â t
Nyhedshistorier
Fra webkilder og nyhedspartnere
Yahoo Finance
·
for 3 timer siden
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
ad-hoc-news.de
·
for 3 timer siden
Wells Fargo cuts Alnylam target to USD 253 for Alnylam Pharmaceuticals stock
Profil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Om Alnylam Pharmaceuticals, Inc.
Administrerende direktørYvonne Greenstreet
Ansatte2,5Â t
Grundlagt14. jun. 2002
Hovedsæde-
Sektor-
Websitealnylam.com